A clinical study of THEO-260 administered by intraperitoneal delivery to advanced ovarian cancer
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs THEO 260 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 27 Nov 2024 New trial record